Structure and Optimization of Checkpoint Inhibitors

With the advent of checkpoint inhibitor treatment for various cancer types, the optimization of drug selection, pharmacokinetics and biomarker assays is an urgent and as yet unresolved dilemma for clinicians, pharmaceutical companies and researchers. Drugs which inhibit cytotoxic T-lymphocyte associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Picardo, Sarah L., Doi, Jeffrey, Hansen, Aaron R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017177/
https://www.ncbi.nlm.nih.gov/pubmed/31877721
http://dx.doi.org/10.3390/cancers12010038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017177/
https://www.ncbi.nlm.nih.gov/pubmed/31877721
http://dx.doi.org/10.3390/cancers12010038

Ejemplares similares